Their results indicated that engaging the IGF-1/IGF-1R system might enable tumor cells to escape anti-EGFR-mediated treatment as a consequence of IGF-1-driven stimulation of the PI3K–Akt pathway[53]. Here, IGF1R is linked to neoplasm.